APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chemotherapy Induced Neutropenia Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Chemotherapy Induced Neutropenia Drug Industry Research Report 2026

19 December 2025144 pages

Choose your research edition.

Industry ResearchChemotherapy Induced Neutropenia Drug Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotherapy Induced Neutropenia Drug Industry Growth and Trends Forecast to 2032128 pages · $3,450 USDMarket StructureGlobal Chemotherapy Induced Neutropenia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotherapy Induced Neutropenia Drug Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotherapy Induced Neutropenia Drug Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Chemotherapy Induced Neutropenia Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Chemotherapy Induced Neutropenia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Chemotherapy Induced Neutropenia Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Chemotherapy Induced Neutropenia Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Chemotherapy Induced Neutropenia Drug include Sandoz International GmbH, Pfizer Inc, USV Pvt Ltd, Richter Gedeon Nyrt, Reliance Life Sciences Pvt Ltd, Pfenex Inc, Pangen Biotech Inc., Octapharma AG and Nohla Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Chemotherapy Induced Neutropenia Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Chemotherapy Induced Neutropenia Drug Market by Company

Sandoz International GmbH

Pfizer Inc

USV Pvt Ltd

Richter Gedeon Nyrt

Reliance Life Sciences Pvt Ltd

Pfenex Inc

Pangen Biotech Inc.

Octapharma AG

Nohla Therapeutics Inc

Myelo Therapeutics GmbH

Mycenax Biotech Inc

Lupin Ltd

Intas Pharmaceuticals Ltd

Hanmi Pharmaceuticals Co Ltd

GlycoMimetics Inc

Genexine Inc

Generon (Shanghai) Corp Ltd

Gene Techno Science Co Ltd

Dr. Reddy's Laboratories Ltd

Cinfa Biotech SL

Chong Kun Dang Pharmaceutical Corp

Cellerant Therapeutics Inc

Bolder Biotechnology Inc

Biocon Ltd

BeyondSpring Pharmaceuticals Inc

Chemotherapy Induced Neutropenia Drug Segment by Type

Filgrastim

NLA-101

GW-003

F-627

BBT-018

Others

Chemotherapy Induced Neutropenia Drug Segment by Application

Hospital

Clinic

Others

Chemotherapy Induced Neutropenia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy Induced Neutropenia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy Induced Neutropenia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy Induced Neutropenia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Chemotherapy Induced Neutropenia Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Chemotherapy Induced Neutropenia Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Chemotherapy Induced Neutropenia Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Chemotherapy Induced Neutropenia Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Chemotherapy Induced Neutropenia Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Chemotherapy Induced Neutropenia Drug Revenue of Manufacturers (2021-2026) Table 9. Global Chemotherapy Induced Neutropenia Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Chemotherapy Induced Neutropenia Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Chemotherapy Induced Neutropenia Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Chemotherapy Induced Neutropenia Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Chemotherapy Induced Neutropenia Drug, Product Type & Application Table 14. Global Chemotherapy Induced Neutropenia Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Chemotherapy Induced Neutropenia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sandoz International GmbH Company Information Table 19. Sandoz International GmbH Business Overview Table 20. Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio Table 22. Sandoz International GmbH Recent Developments Table 23. Pfizer Inc Company Information Table 24. Pfizer Inc Business Overview Table 25. Pfizer Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Pfizer Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 27. Pfizer Inc Recent Developments Table 28. USV Pvt Ltd Company Information Table 29. USV Pvt Ltd Business Overview Table 30. USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 32. USV Pvt Ltd Recent Developments Table 33. Richter Gedeon Nyrt Company Information Table 34. Richter Gedeon Nyrt Business Overview Table 35. Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Product Portfolio Table 37. Richter Gedeon Nyrt Recent Developments Table 38. Reliance Life Sciences Pvt Ltd Company Information Table 39. Reliance Life Sciences Pvt Ltd Business Overview Table 40. Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 42. Reliance Life Sciences Pvt Ltd Recent Developments Table 43. Pfenex Inc Company Information Table 44. Pfenex Inc Business Overview Table 45. Pfenex Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Pfenex Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 47. Pfenex Inc Recent Developments Table 48. Pangen Biotech Inc. Company Information Table 49. Pangen Biotech Inc. Business Overview Table 50. Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Product Portfolio Table 52. Pangen Biotech Inc. Recent Developments Table 53. Octapharma AG Company Information Table 54. Octapharma AG Business Overview Table 55. Octapharma AG Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Octapharma AG Chemotherapy Induced Neutropenia Drug Product Portfolio Table 57. Octapharma AG Recent Developments Table 58. Nohla Therapeutics Inc Company Information Table 59. Nohla Therapeutics Inc Business Overview Table 60. Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 62. Nohla Therapeutics Inc Recent Developments Table 63. Myelo Therapeutics GmbH Company Information Table 64. Myelo Therapeutics GmbH Business Overview Table 65. Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio Table 67. Myelo Therapeutics GmbH Recent Developments Table 68. Mycenax Biotech Inc Company Information Table 69. Mycenax Biotech Inc Business Overview Table 70. Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 72. Mycenax Biotech Inc Recent Developments Table 73. Lupin Ltd Company Information Table 74. Lupin Ltd Business Overview Table 75. Lupin Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Lupin Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 77. Lupin Ltd Recent Developments Table 78. Intas Pharmaceuticals Ltd Company Information Table 79. Intas Pharmaceuticals Ltd Business Overview Table 80. Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 82. Intas Pharmaceuticals Ltd Recent Developments Table 83. Hanmi Pharmaceuticals Co Ltd Company Information Table 84. Hanmi Pharmaceuticals Co Ltd Business Overview Table 85. Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 87. Hanmi Pharmaceuticals Co Ltd Recent Developments Table 88. GlycoMimetics Inc Company Information Table 89. GlycoMimetics Inc Business Overview Table 90. GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 92. GlycoMimetics Inc Recent Developments Table 93. Genexine Inc Company Information Table 94. Genexine Inc Business Overview Table 95. Genexine Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Genexine Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 97. Genexine Inc Recent Developments Table 98. Generon (Shanghai) Corp Ltd Company Information Table 99. Generon (Shanghai) Corp Ltd Business Overview Table 100. Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 102. Generon (Shanghai) Corp Ltd Recent Developments Table 103. Gene Techno Science Co Ltd Company Information Table 104. Gene Techno Science Co Ltd Business Overview Table 105. Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 107. Gene Techno Science Co Ltd Recent Developments Table 108. Dr. Reddy's Laboratories Ltd Company Information Table 109. Dr. Reddy's Laboratories Ltd Business Overview Table 110. Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 112. Dr. Reddy's Laboratories Ltd Recent Developments Table 113. Cinfa Biotech SL Company Information Table 114. Cinfa Biotech SL Business Overview Table 115. Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Product Portfolio Table 117. Cinfa Biotech SL Recent Developments Table 118. Chong Kun Dang Pharmaceutical Corp Company Information Table 119. Chong Kun Dang Pharmaceutical Corp Business Overview Table 120. Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Product Portfolio Table 122. Chong Kun Dang Pharmaceutical Corp Recent Developments Table 123. Cellerant Therapeutics Inc Company Information Table 124. Cellerant Therapeutics Inc Business Overview Table 125. Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 127. Cellerant Therapeutics Inc Recent Developments Table 128. Bolder Biotechnology Inc Company Information Table 129. Bolder Biotechnology Inc Business Overview Table 130. Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 132. Bolder Biotechnology Inc Recent Developments Table 133. Biocon Ltd Company Information Table 134. Biocon Ltd Business Overview Table 135. Biocon Ltd Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Biocon Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio Table 137. Biocon Ltd Recent Developments Table 138. BeyondSpring Pharmaceuticals Inc Company Information Table 139. BeyondSpring Pharmaceuticals Inc Business Overview Table 140. BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Product Portfolio Table 142. BeyondSpring Pharmaceuticals Inc Recent Developments Table 143. Global Chemotherapy Induced Neutropenia Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 144. Global Chemotherapy Induced Neutropenia Drug Sales by Region (2021-2026) & (K Units) Table 145. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Region (2021-2026) Table 146. Global Chemotherapy Induced Neutropenia Drug Sales by Region (2027-2032) & (K Units) Table 147. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Region (2027-2032) Table 148. Global Chemotherapy Induced Neutropenia Drug Revenue by Region (2021-2026) & (US$ Million) Table 149. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Region (2021-2026) Table 150. Global Chemotherapy Induced Neutropenia Drug Revenue by Region (2027-2032) & (US$ Million) Table 151. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Region (2027-2032) Table 152. North America Chemotherapy Induced Neutropenia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. North America Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 154. North America Chemotherapy Induced Neutropenia Drug Sales by Country (2027-2032) & (K Units) Table 155. North America Chemotherapy Induced Neutropenia Drug Revenue by Country (2021-2026) & (US$ Million) Table 156. North America Chemotherapy Induced Neutropenia Drug Revenue by Country (2027-2032) & (US$ Million) Table 157. Europe Chemotherapy Induced Neutropenia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Europe Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 159. Europe Chemotherapy Induced Neutropenia Drug Sales by Country (2027-2032) & (K Units) Table 160. Europe Chemotherapy Induced Neutropenia Drug Revenue by Country (2021-2026) & (US$ Million) Table 161. Europe Chemotherapy Induced Neutropenia Drug Revenue by Country (2027-2032) & (US$ Million) Table 162. Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 164. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Country (2027-2032) & (K Units) Table 165. Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue by Country (2021-2026) & (US$ Million) Table 166. Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue by Country (2027-2032) & (US$ Million) Table 167. South America Chemotherapy Induced Neutropenia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. South America Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 169. South America Chemotherapy Induced Neutropenia Drug Sales by Country (2027-2032) & (K Units) Table 170. South America Chemotherapy Induced Neutropenia Drug Revenue by Country (2021-2026) & (US$ Million) Table 171. South America Chemotherapy Induced Neutropenia Drug Revenue by Country (2027-2032) & (US$ Million) Table 172. Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 173. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2026) & (K Units) Table 174. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country (2027-2032) & (K Units) Table 175. Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue by Country (2021-2026) & (US$ Million) Table 176. Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue by Country (2027-2032) & (US$ Million) Table 177. Global Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2026) & (K Units) Table 178. Global Chemotherapy Induced Neutropenia Drug Sales by Type (2027-2032) & (K Units) Table 179. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2021-2026) Table 180. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2027-2032) Table 181. Global Chemotherapy Induced Neutropenia Drug Revenue by Type (2021-2026) & (US$ Million) Table 182. Global Chemotherapy Induced Neutropenia Drug Revenue by Type (2027-2032) & (US$ Million) Table 183. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Type (2021-2026) Table 184. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Type (2027-2032) Table 185. Global Chemotherapy Induced Neutropenia Drug Price by Type (2021-2026) & (US$/Unit) Table 186. Global Chemotherapy Induced Neutropenia Drug Price by Type (2027-2032) & (US$/Unit) Table 187. Global Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2026) & (K Units) Table 188. Global Chemotherapy Induced Neutropenia Drug Sales by Application (2027-2032) & (K Units) Table 189. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2021-2026) Table 190. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2027-2032) Table 191. Global Chemotherapy Induced Neutropenia Drug Revenue by Application (2021-2026) & (US$ Million) Table 192. Global Chemotherapy Induced Neutropenia Drug Revenue by Application (2027-2032) & (US$ Million) Table 193. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Application (2021-2026) Table 194. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Application (2027-2032) Table 195. Global Chemotherapy Induced Neutropenia Drug Price by Application (2021-2026) & (US$/Unit) Table 196. Global Chemotherapy Induced Neutropenia Drug Price by Application (2027-2032) & (US$/Unit) Table 197. Key Raw Materials Table 198. Raw Materials Key Suppliers Table 199. Chemotherapy Induced Neutropenia Drug Distributors List Table 200. Chemotherapy Induced Neutropenia Drug Customers List Table 201. Chemotherapy Induced Neutropenia Drug Industry Trends Table 202. Chemotherapy Induced Neutropenia Drug Industry Drivers Table 203. Chemotherapy Induced Neutropenia Drug Industry Restraints Table 204. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Chemotherapy Induced Neutropenia Drug Product Image Figure 5. Global Chemotherapy Induced Neutropenia Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Chemotherapy Induced Neutropenia Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Chemotherapy Induced Neutropenia Drug Sales (2021-2032) & (K Units) Figure 8. Global Chemotherapy Induced Neutropenia Drug Average Price (US$/Unit) & (2021-2032) Figure 9. Filgrastim Product Image Figure 10. NLA-101 Product Image Figure 11. GW-003 Product Image Figure 12. F-627 Product Image Figure 13. BBT-018 Product Image Figure 14. Others Product Image Figure 15. Hospital Product Image Figure 16. Clinic Product Image Figure 17. Others Product Image Figure 18. Global Chemotherapy Induced Neutropenia Drug Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Chemotherapy Induced Neutropenia Drug, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Chemotherapy Induced Neutropenia Drug Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Chemotherapy Induced Neutropenia Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Chemotherapy Induced Neutropenia Drug Sales by Region in 2025 Figure 24. Global Chemotherapy Induced Neutropenia Drug Revenue by Region in 2025 Figure 25. North America Chemotherapy Induced Neutropenia Drug Market Size by Country in 2025 Figure 26. North America Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2032) Figure 27. North America Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country (2021-2032) Figure 28. United States Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Chemotherapy Induced Neutropenia Drug Market Size by Country in 2025 Figure 31. Europe Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2032) Figure 32. Europe Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country (2021-2032) Figure 33. Germany Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Asia Pacific Chemotherapy Induced Neutropenia Drug Market Size by Country in 2025 Figure 39. Asia Pacific Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2032) Figure 40. Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country (2021-2032) Figure 41. China Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Japan Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. South Korea Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. India Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Australia Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. China Taiwan Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South America Chemotherapy Induced Neutropenia Drug Market Size by Country in 2025 Figure 50. South America Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2032) Figure 51. South America Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country (2021-2032) Figure 52. Mexico Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Brazil Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size by Country in 2025 Figure 56. Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales Market Share by Country (2021-2032) Figure 57. Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue Market Share by Country (2021-2032) Figure 58. Turkey Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. UAE Chemotherapy Induced Neutropenia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2021-2032) Figure 62. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Type (2021-2032) Figure 63. Global Chemotherapy Induced Neutropenia Drug Price (US$/Unit) by Type (2021-2032) Figure 64. Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2021-2032) Figure 65. Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Application (2021-2032) Figure 66. Global Chemotherapy Induced Neutropenia Drug Price (US$/Unit) by Application (2021-2032) Figure 67. Chemotherapy Induced Neutropenia Drug Value Chain Figure 68. Chemotherapy Induced Neutropenia Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Chemotherapy Induced Neutropenia Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Filgrastim
  • NLA-101
  • GW-003
  • F-627
  • BBT-018
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Sandoz International GmbH
  • Pfizer Inc
  • USV Pvt Ltd
  • Richter Gedeon Nyrt
  • Reliance Life Sciences Pvt Ltd
  • Pfenex Inc
  • Pangen Biotech Inc.
  • Octapharma AG
  • Nohla Therapeutics Inc
  • Myelo Therapeutics GmbH
  • Mycenax Biotech Inc
  • Lupin Ltd
  • Intas Pharmaceuticals Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • GlycoMimetics Inc
  • Genexine Inc
  • Generon (Shanghai) Corp Ltd
  • Gene Techno Science Co Ltd
  • Dr. Reddy's Laboratories Ltd
  • Cinfa Biotech SL
  • Chong Kun Dang Pharmaceutical Corp
  • Cellerant Therapeutics Inc
  • Bolder Biotechnology Inc
  • Biocon Ltd
  • BeyondSpring Pharmaceuticals Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Chemotherapy Induced Neutropenia Drug Market Size (2021-2032)
  4. 2.2.2 Global Chemotherapy Induced Neutropenia Drug Sales (2021-2032)
  5. 2.2.3 Global Chemotherapy Induced Neutropenia Drug Market Average Price (2021-2032)
  6. 2.3 Chemotherapy Induced Neutropenia Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Filgrastim
  9. 2.3.3 NLA-101
  10. 2.3.4 GW-003
  11. 2.3.5 F-627
  12. 2.3.6 BBT-018
  13. 2.3.7 Others
  14. 2.4 Chemotherapy Induced Neutropenia Drug by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Hospital
  17. 2.4.3 Clinic
  18. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Chemotherapy Induced Neutropenia Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Chemotherapy Induced Neutropenia Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Chemotherapy Induced Neutropenia Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Chemotherapy Induced Neutropenia Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Chemotherapy Induced Neutropenia Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Chemotherapy Induced Neutropenia Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Chemotherapy Induced Neutropenia Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Chemotherapy Induced Neutropenia Drug, Established Date
  9. 3.9 Global Chemotherapy Induced Neutropenia Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sandoz International GmbH
  2. 4.1.1 Sandoz International GmbH Company Information
  3. 4.1.2 Sandoz International GmbH Business Overview
  4. 4.1.3 Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio
  6. 4.1.5 Sandoz International GmbH Recent Developments
  7. 4.2 Pfizer Inc
  8. 4.2.1 Pfizer Inc Company Information
  9. 4.2.2 Pfizer Inc Business Overview
  10. 4.2.3 Pfizer Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Pfizer Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  12. 4.2.5 Pfizer Inc Recent Developments
  13. 4.3 USV Pvt Ltd
  14. 4.3.1 USV Pvt Ltd Company Information
  15. 4.3.2 USV Pvt Ltd Business Overview
  16. 4.3.3 USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  18. 4.3.5 USV Pvt Ltd Recent Developments
  19. 4.4 Richter Gedeon Nyrt
  20. 4.4.1 Richter Gedeon Nyrt Company Information
  21. 4.4.2 Richter Gedeon Nyrt Business Overview
  22. 4.4.3 Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Product Portfolio
  24. 4.4.5 Richter Gedeon Nyrt Recent Developments
  25. 4.5 Reliance Life Sciences Pvt Ltd
  26. 4.5.1 Reliance Life Sciences Pvt Ltd Company Information
  27. 4.5.2 Reliance Life Sciences Pvt Ltd Business Overview
  28. 4.5.3 Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  30. 4.5.5 Reliance Life Sciences Pvt Ltd Recent Developments
  31. 4.6 Pfenex Inc
  32. 4.6.1 Pfenex Inc Company Information
  33. 4.6.2 Pfenex Inc Business Overview
  34. 4.6.3 Pfenex Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfenex Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  36. 4.6.5 Pfenex Inc Recent Developments
  37. 4.7 Pangen Biotech Inc.
  38. 4.7.1 Pangen Biotech Inc. Company Information
  39. 4.7.2 Pangen Biotech Inc. Business Overview
  40. 4.7.3 Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Product Portfolio
  42. 4.7.5 Pangen Biotech Inc. Recent Developments
  43. 4.8 Octapharma AG
  44. 4.8.1 Octapharma AG Company Information
  45. 4.8.2 Octapharma AG Business Overview
  46. 4.8.3 Octapharma AG Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Octapharma AG Chemotherapy Induced Neutropenia Drug Product Portfolio
  48. 4.8.5 Octapharma AG Recent Developments
  49. 4.9 Nohla Therapeutics Inc
  50. 4.9.1 Nohla Therapeutics Inc Company Information
  51. 4.9.2 Nohla Therapeutics Inc Business Overview
  52. 4.9.3 Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  54. 4.9.5 Nohla Therapeutics Inc Recent Developments
  55. 4.10 Myelo Therapeutics GmbH
  56. 4.10.1 Myelo Therapeutics GmbH Company Information
  57. 4.10.2 Myelo Therapeutics GmbH Business Overview
  58. 4.10.3 Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio
  60. 4.10.5 Myelo Therapeutics GmbH Recent Developments
  61. 4.11 Mycenax Biotech Inc
  62. 4.11.1 Mycenax Biotech Inc Company Information
  63. 4.11.2 Mycenax Biotech Inc Business Overview
  64. 4.11.3 Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  66. 4.11.5 Mycenax Biotech Inc Recent Developments
  67. 4.12 Lupin Ltd
  68. 4.12.1 Lupin Ltd Company Information
  69. 4.12.2 Lupin Ltd Business Overview
  70. 4.12.3 Lupin Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Lupin Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  72. 4.12.5 Lupin Ltd Recent Developments
  73. 4.13 Intas Pharmaceuticals Ltd
  74. 4.13.1 Intas Pharmaceuticals Ltd Company Information
  75. 4.13.2 Intas Pharmaceuticals Ltd Business Overview
  76. 4.13.3 Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  78. 4.13.5 Intas Pharmaceuticals Ltd Recent Developments
  79. 4.14 Hanmi Pharmaceuticals Co Ltd
  80. 4.14.1 Hanmi Pharmaceuticals Co Ltd Company Information
  81. 4.14.2 Hanmi Pharmaceuticals Co Ltd Business Overview
  82. 4.14.3 Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  84. 4.14.5 Hanmi Pharmaceuticals Co Ltd Recent Developments
  85. 4.15 GlycoMimetics Inc
  86. 4.15.1 GlycoMimetics Inc Company Information
  87. 4.15.2 GlycoMimetics Inc Business Overview
  88. 4.15.3 GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  90. 4.15.5 GlycoMimetics Inc Recent Developments
  91. 4.16 Genexine Inc
  92. 4.16.1 Genexine Inc Company Information
  93. 4.16.2 Genexine Inc Business Overview
  94. 4.16.3 Genexine Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Genexine Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  96. 4.16.5 Genexine Inc Recent Developments
  97. 4.17 Generon (Shanghai) Corp Ltd
  98. 4.17.1 Generon (Shanghai) Corp Ltd Company Information
  99. 4.17.2 Generon (Shanghai) Corp Ltd Business Overview
  100. 4.17.3 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  102. 4.17.5 Generon (Shanghai) Corp Ltd Recent Developments
  103. 4.18 Gene Techno Science Co Ltd
  104. 4.18.1 Gene Techno Science Co Ltd Company Information
  105. 4.18.2 Gene Techno Science Co Ltd Business Overview
  106. 4.18.3 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  108. 4.18.5 Gene Techno Science Co Ltd Recent Developments
  109. 4.19 Dr. Reddy's Laboratories Ltd
  110. 4.19.1 Dr. Reddy's Laboratories Ltd Company Information
  111. 4.19.2 Dr. Reddy's Laboratories Ltd Business Overview
  112. 4.19.3 Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  114. 4.19.5 Dr. Reddy's Laboratories Ltd Recent Developments
  115. 4.20 Cinfa Biotech SL
  116. 4.20.1 Cinfa Biotech SL Company Information
  117. 4.20.2 Cinfa Biotech SL Business Overview
  118. 4.20.3 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Product Portfolio
  120. 4.20.5 Cinfa Biotech SL Recent Developments
  121. 4.21 Chong Kun Dang Pharmaceutical Corp
  122. 4.21.1 Chong Kun Dang Pharmaceutical Corp Company Information
  123. 4.21.2 Chong Kun Dang Pharmaceutical Corp Business Overview
  124. 4.21.3 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Product Portfolio
  126. 4.21.5 Chong Kun Dang Pharmaceutical Corp Recent Developments
  127. 4.22 Cellerant Therapeutics Inc
  128. 4.22.1 Cellerant Therapeutics Inc Company Information
  129. 4.22.2 Cellerant Therapeutics Inc Business Overview
  130. 4.22.3 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  132. 4.22.5 Cellerant Therapeutics Inc Recent Developments
  133. 4.23 Bolder Biotechnology Inc
  134. 4.23.1 Bolder Biotechnology Inc Company Information
  135. 4.23.2 Bolder Biotechnology Inc Business Overview
  136. 4.23.3 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  138. 4.23.5 Bolder Biotechnology Inc Recent Developments
  139. 4.24 Biocon Ltd
  140. 4.24.1 Biocon Ltd Company Information
  141. 4.24.2 Biocon Ltd Business Overview
  142. 4.24.3 Biocon Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Biocon Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
  144. 4.24.5 Biocon Ltd Recent Developments
  145. 4.25 BeyondSpring Pharmaceuticals Inc
  146. 4.25.1 BeyondSpring Pharmaceuticals Inc Company Information
  147. 4.25.2 BeyondSpring Pharmaceuticals Inc Business Overview
  148. 4.25.3 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
  150. 4.25.5 BeyondSpring Pharmaceuticals Inc Recent Developments
5 Global Chemotherapy Induced Neutropenia Drug Market Scenario by Region
  1. 5.1 Global Chemotherapy Induced Neutropenia Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Chemotherapy Induced Neutropenia Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Chemotherapy Induced Neutropenia Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Chemotherapy Induced Neutropenia Drug Sales by Region: 2027-2032
  5. 5.3 Global Chemotherapy Induced Neutropenia Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Chemotherapy Induced Neutropenia Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Region: 2027-2032
  8. 5.4 North America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Country
  9. 5.4.1 North America Chemotherapy Induced Neutropenia Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Chemotherapy Induced Neutropenia Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Chemotherapy Induced Neutropenia Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Chemotherapy Induced Neutropenia Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Chemotherapy Induced Neutropenia Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Country
  35. 5.7.1 South America Chemotherapy Induced Neutropenia Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Chemotherapy Induced Neutropenia Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Chemotherapy Induced Neutropenia Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Chemotherapy Induced Neutropenia Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Chemotherapy Induced Neutropenia Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Chemotherapy Induced Neutropenia Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Chemotherapy Induced Neutropenia Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Chemotherapy Induced Neutropenia Drug Value Chain Analysis
  2. 8.1.1 Chemotherapy Induced Neutropenia Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Chemotherapy Induced Neutropenia Drug Production Mode & Process
  5. 8.2 Chemotherapy Induced Neutropenia Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Chemotherapy Induced Neutropenia Drug Distributors
  8. 8.2.3 Chemotherapy Induced Neutropenia Drug Customers
9 Global Chemotherapy Induced Neutropenia Drug Analyzing Market Dynamics
  1. 9.1 Chemotherapy Induced Neutropenia Drug Industry Trends
  2. 9.2 Chemotherapy Induced Neutropenia Drug Industry Drivers
  3. 9.3 Chemotherapy Induced Neutropenia Drug Industry Opportunities and Challenges
  4. 9.4 Chemotherapy Induced Neutropenia Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst